Logo image of INVE

IDENTIV INC (INVE) Stock Fundamental Analysis

NASDAQ:INVE - Nasdaq - US45170X2053 - Common Stock - Currency: USD

3.45  +0.05 (+1.47%)

After market: 3.49 +0.04 (+1.16%)

Fundamental Rating

4

INVE gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 125 industry peers in the Electronic Equipment, Instruments & Components industry. No worries on liquidiy or solvency for INVE as it has an excellent financial health rating, but there are worries on the profitability. INVE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year INVE has reported negative net income.
INVE had a negative operating cash flow in the past year.
In multiple years INVE reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: INVE reported negative operating cash flow in multiple years.
INVE Yearly Net Income VS EBIT VS OCF VS FCFINVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

1.2 Ratios

INVE has a better Return On Assets (46.46%) than 100.00% of its industry peers.
With an excellent Return On Equity value of 49.00%, INVE belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
ROA 46.46%
ROE 49%
ROIC N/A
ROA(3y)12.53%
ROA(5y)6.04%
ROE(3y)12.26%
ROE(5y)3.86%
ROIC(3y)N/A
ROIC(5y)N/A
INVE Yearly ROA, ROE, ROICINVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

INVE has a Profit Margin of 292.20%. This is amongst the best in the industry. INVE outperforms 100.00% of its industry peers.
INVE's Profit Margin has improved in the last couple of years.
The Operating Margin and Gross Margin are not available for INVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 292.2%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y732.24%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INVE Yearly Profit, Operating, Gross MarginsINVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

More info and screens

8

2. Health

2.1 Basic Checks

INVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
INVE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for INVE has been increased compared to 5 years ago.
There is no outstanding debt for INVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INVE Yearly Shares OutstandingINVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
INVE Yearly Total Debt VS Total AssetsINVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 3.46 indicates that INVE is not in any danger for bankruptcy at the moment.
INVE's Altman-Z score of 3.46 is in line compared to the rest of the industry. INVE outperforms 56.80% of its industry peers.
There is no outstanding debt for INVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.46
ROIC/WACCN/A
WACC9.6%
INVE Yearly LT Debt VS Equity VS FCFINVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

INVE has a Current Ratio of 20.51. This indicates that INVE is financially healthy and has no problem in meeting its short term obligations.
INVE's Current ratio of 20.51 is amongst the best of the industry. INVE outperforms 97.60% of its industry peers.
A Quick Ratio of 19.44 indicates that INVE has no problem at all paying its short term obligations.
INVE has a Quick ratio of 19.44. This is amongst the best in the industry. INVE outperforms 97.60% of its industry peers.
Industry RankSector Rank
Current Ratio 20.51
Quick Ratio 19.44
INVE Yearly Current Assets VS Current LiabilitesINVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

INVE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -194.44%.
Measured over the past years, INVE shows a very strong growth in Earnings Per Share. The EPS has been growing by 438.90% on average per year.
INVE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -73.99%.
INVE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.49% yearly.
EPS 1Y (TTM)-194.44%
EPS 3Y438.9%
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-73.99%
Revenue growth 3Y-36.46%
Revenue growth 5Y-20.49%
Sales Q2Q%-76.58%

3.2 Future

The Earnings Per Share is expected to grow by 5.73% on average over the next years.
The Revenue is expected to grow by 30.86% on average over the next years. This is a very strong growth
EPS Next Y9.23%
EPS Next 2Y5.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-53.46%
Revenue Next 2Y-28.78%
Revenue Next 3Y40.96%
Revenue Next 5Y30.86%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INVE Yearly Revenue VS EstimatesINVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M
INVE Yearly EPS VS EstimatesINVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INVE. In the last year negative earnings were reported.
Also next year INVE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INVE Price Earnings VS Forward Price EarningsINVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INVE Per share dataINVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.73%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

INVE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IDENTIV INC

NASDAQ:INVE (7/21/2025, 5:27:54 PM)

After market: 3.49 +0.04 (+1.16%)

3.45

+0.05 (+1.47%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners57.38%
Inst Owner Change0%
Ins Owners11.56%
Ins Owner Change0.1%
Market Cap81.49M
Analysts82.22
Price Target5.95 (72.46%)
Short Float %0.89%
Short Ratio2.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.33%
Min EPS beat(2)14.22%
Max EPS beat(2)38.44%
EPS beat(4)2
Avg EPS beat(4)-12.03%
Min EPS beat(4)-58.98%
Max EPS beat(4)38.44%
EPS beat(8)3
Avg EPS beat(8)-45.11%
EPS beat(12)5
Avg EPS beat(12)-37.29%
EPS beat(16)8
Avg EPS beat(16)-45.88%
Revenue beat(2)2
Avg Revenue beat(2)5.85%
Min Revenue beat(2)4.36%
Max Revenue beat(2)7.34%
Revenue beat(4)3
Avg Revenue beat(4)4.68%
Min Revenue beat(4)-0.6%
Max Revenue beat(4)7.63%
Revenue beat(8)3
Avg Revenue beat(8)-0.5%
Revenue beat(12)3
Avg Revenue beat(12)-2.3%
Revenue beat(16)5
Avg Revenue beat(16)-1.81%
PT rev (1m)0%
PT rev (3m)-14.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.23
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.54
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS1.07
BVpS6.37
TBVpS6.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 46.46%
ROE 49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 292.2%
GM N/A
FCFM N/A
ROA(3y)12.53%
ROA(5y)6.04%
ROE(3y)12.26%
ROE(5y)3.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y732.24%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.05%
Cap/Sales 6.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.51
Quick Ratio 19.44
Altman-Z 3.46
F-Score4
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)126.88%
Cap/Depr(5y)106.77%
Cap/Sales(3y)6.31%
Cap/Sales(5y)4.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-194.44%
EPS 3Y438.9%
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y9.23%
EPS Next 2Y5.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-73.99%
Revenue growth 3Y-36.46%
Revenue growth 5Y-20.49%
Sales Q2Q%-76.58%
Revenue Next Year-53.46%
Revenue Next 2Y-28.78%
Revenue Next 3Y40.96%
Revenue Next 5Y30.86%
EBIT growth 1Y-301.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.22%
EBIT Next 3Y45.38%
EBIT Next 5Y33.76%
FCF growth 1Y-10.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.52%
OCF growth 3YN/A
OCF growth 5YN/A